# US 2021/0276967 A1 · Inhibitors of hepatitis b virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0276967 A1
- Document ID: US20210276967A1
- Status: Published application
- Kind: A1
- Application number: 17/261,223
- Filed: 2019-07-19
- Published: 2021-09-09
- Earliest claimed: 2018-07-19
- Assignees: Ospedale San Raffaele S.R.L.; Irbm S.P.A.; Promidis S.R.L.; Istituto Nazionale Di Genetica Molecolare - Ingm
- Applicants: Ospedale San Raffaele S.R.L.; Irbm S.P.A.; Promidis S.R.L.; Istituto Nazionale Di Genetica Molecolare - Ingm
- Inventors: Raffaele DE FRANCESCO; Adolfo PRANDI; Pietro RANDAZZO; Lorena DONNICI; Luca GUIDOTTI; Matteo IANNACONE; Romano DI FABIO; Vincenzo SUMMA; Leda Ivanova BENCHEVA; Marilenia DE MATTEO; Luca FERRANTE
- Web page: https://patentgrep.com/patent/US20210276967A1

## CPC

- C07D 211/58: attached in position 4
- C07D 305/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/18: for HIV
- C07C 311/16: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C 311/39: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C 311/40: to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 311/43: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 207/48: Sulfur atoms
- C07D 211/96: Sulfur atom
- C07D 213/42: having hetero atoms attached to the substituent nitrogen atom (nitro radicals C07D213/26)
- C07D 213/73: Unsubstituted amino or imino radicals
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/76: to which a second hetero atom is attached (nitro radicals C07D213/61)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

## Claims

### Claim 1

A compound of general formula (I):
wherein:
A is a 6-membered aromatic or heteroaromatic ring;
B is a 6-membered aryl optionally containing one or more N atoms;
X is H or NR3R4;
Y is selected from the group consisting of hydrogen, halogen, C1-6alkyl, NH2, NH(C1-6alkyl), N(CH3)2, NHC(O)CH3, OH, saturated or partially unsaturated C3-7cycloalkyl, 5- or 6-membered heteroaryl and CN or is absent;
with the proviso that, when X is H, Y is selected form the group consisting of NH2, NH(C1-6alkyl), N(CH3)2, NHC(O)CH3;
R1 and R2 are each independently selected from H, linear or branched C1-6alkyl, saturated or partially unsaturated
C3-7 cycloalkyl, C3-7heterocycloalkyl and heteroaryl, each of said linear or branched C1-6alkyl, saturated or partially unsaturated C3-7cycloalkyl, C3-7heterocycloalkyl or heteroaryl group being optionally substituted with one or more substituents selected from OH, halogen, NH2, NH(C═O)OC1-6alkyl, NH(C1-6alkyl), C1-6alkyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C1-6hydroxyalkyl, 5- or 6-membered heteroaryl, C(═O)C1-6alkyl, C(═O)OC1-6alkyl, OC1-6alkyl, O(CH2)nC3-10cycloalkyl and O(CH2)nC3-10 heterocycloalkyl;
or R1 and R2 taken together form with the N atom to which they are attached a saturated or partially unsaturated 3-10 membered heterocyclic ring optionally containing another heteroatom selected from N, O and S, said saturated or partially unsaturated 3-10 membered heterocyclic ring being optionally substituted with one or more substituents selected from OH, halogen, C1-6alkyl, C1-6haloalkyl and (CH2)nR5;
each occurrence of n is independently 0, 1, 2, 3 or 4;
R3 and R4 are each independently H, or linear or branched C1-3alkyl optionally substituted with one or more groups selected from halogen, NH2, NHC1-6alkyl, N(C1-6alkyl)2, NH(C═O)C1-6alkyl, NH(C═O)OC1-6alkyl, OC1-6alkyl, O(CH2)nC3-10cycloalkyl and O(CH2)nC3-10heterocycloalkyl, with the proviso that NR3R4 does not form a saturated, partially saturated or unsaturated heterocyclic ring;
R5 is selected from the group consisting of OH, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, CN, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, heterocyclic ring, aryl and heteroaryl;
Ra is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O) CH3, OH and CN; or is absent;
Rb is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN; or is absent;
Rc is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN; or is absent;
Rd is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN; or is absent;
Re is selected from the group consisting of hydrogen, halogen, C1-3alkyl; or is absent;
Rf is hydrogen, halogen, C1-3alkyl; or is absent;
provided that the compound is not 2-amino-N-(4-chloro-2-methylphenyl)-5-sulfamoylbenzamide or N-(2-methoxyphenyl)-2-(methylamino)-5-(piperidin-1-ylsulfonyl)benzamide;
and pharmaceutically acceptable salts, tautomers, isomers, stereoisomers thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 having formula (Ia):
wherein:
A is a 6-membered aromatic or heteroaromatic ring;
B is a 6-membered aryl optionally containing one or more N atoms;
Y is selected from the group consisting of hydrogen, halogen, C1-3alkyl, NH2, NH(C1-6alkyl), N(CH3)2, NHC(O)CH3, OH, saturated or partially unsaturated C3-7cycloalkyl, 5- or 6-membered heteroaryl and CN or is absent;
R1 and R2 are each independently selected from H, linear or branched C1-6alkyl, saturated or partially unsaturated
C3-7cycloalkyl, C3-7heterocycloalkyl and heteroaryl, each of said linear or branched C1-6alkyl, saturated or partially unsaturated C3-7cycloalkyl, C3-7heterocycloalkyl or heteroaryl group being optionally substituted with one or more substituents selected from OH, halogen, NH2, NH(C═O)OC1-6alkyl, NH(C1-6alkyl), C1-6alkyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C1-6hydroxyalkyl, 5- or 6-membered heteroaryl, C(═O)C1-6alkyl, C(═O)OC1-6alkyl, OC1-6alkyl, O(CH2)nC3-10cycloalkyl and O(CH2)nC3-10 heterocycloalkyl;
or R1 and R2 taken together form with the N atom to which they are attached a saturated or partially unsaturated 3-10 membered heterocyclic ring optionally containing another heteroatom selected from N, O and S, said saturated or partially unsaturated 3-10 membered heterocyclic ring being optionally substituted with one or more substituents selected from OH, halogen, C1-6alkyl, C1-6haloalkyl, (CH2)nR5;
each occurrence of n is independently 0, 1, 2, 3 or 4;
R3 and R4 are each independently H or linear or branched C1-3alkyl optionally substituted with one or more groups selected from halogen, NH2, NHC1-6alkyl, N(C1-6alkyl)2, NH(C═O)C1-6alkyl, NH(C═O)OC1-6alkyl, OC1-6alkyl, O(CH2)nC3-10cycloalkyl and O(CH2)nC3-10heterocycloalkyl, with the proviso that NR3R4 does not form a saturated, partially saturated or unsaturated heterocyclic ring;
R5 is selected from the group consisting of OH, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, CN, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, heterocyclic ring, aryl and heteroaryl;
Ra is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN; or is absent;
Rb is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN; or is absent;
Rc is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN; or is absent;
Rd is selected from the group consisting hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN; or is absent;
Re is selected from the group consisting of hydrogen, halogen and C1-3alkyl; or is absent;
Rf is hydrogen, halogen and C1-3alkyl; or is absent;
and pharmaceutically acceptable salts, tautomers, isomers, stereoisomers thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein:
A is a 6-membered aromatic or heteroaromatic ring;
B is a 6-membered aryl optionally containing one or more N atoms;
Y is selected from the group consisting of hydrogen, halogen, C1-3alkyl, NH2, NH(C1-6alkyl), N(CH3)2, NHC(O)CH3, OH and CN or is absent;
R1 is H, linear or branched C1-6alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pirrolidinyl, oxetanyl, tetrahydrofuranyl, pyridinyl, said C1-6alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pirrolidinyl, oxetanyl, tetrahydrofuranyl or pyridinyl being optionally substituted with one or more substituents selected from OH, halogen, NH2, NH(C═O)OC1-6alkyl, NH(C1-6alkyl), C1-6hydroxyalkyl, 5- or 6-membered heteroaryl, C(═O)C1-6alkyl, C(═O)OC1-6alkyl, OC1-6alkyl;
R2 is H or methyl;
or R1 and R2 taken together form with the N atom to which they are attached a heterocyclic ring selected from piperidine, pirrolidine, morpholine, thiomorpholine and piperazine, said ring being optionally substituted with one or more substituents selected from halogen, C1-3alkyl, OH and CH2R5;
R3 and R4 are each independently H or C1-3alkyl; in particular hydrogen or methyl;
R5 is selected from the group consisting of OH, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, CN, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, heterocyclic ring, aryl and heteroaryl;
Ra is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl and CN; or is absent;
Rb is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl and CN; or is absent;
Rc is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl and CN; or is absent;
Rd is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl and CN; or is absent;
Re is selected from the group consisting of hydrogen, halogen, C1-3alkyl, or is absent;
Rf is hydrogen or is absent;
and pharmaceutically acceptable salts, tautomers, isomers, stereoisomers thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein:
A is a 6-membered aromatic or heteroaromatic ring;
B is a 6-membered aryl optionally containing one or more N atoms;
Y is selected from the group consisting of hydrogen, halogen, C1-3alkyl, or is absent;
R1 is hydrogen, methyl, or is selected from the group consisting of:
R2 is H or methyl;
or R1 and R2 taken together form with the N atom to which they are attached a heterocyclic ring selected from the group consisting of:
R3 and R4 are each independently H or C1-3alkyl; in particular hydrogen or methyl;
Ra is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl and CN; or is absent;
Rb is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl and CN; or is absent;
Rc is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl and CN; or is absent;
Rd is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl and CN; or is absent;
Re is selected from the group consisting of hydrogen, halogen, C1-3alkyl, or is absent;
Rf is hydrogen; or is absent;
and pharmaceutically acceptable salts, tautomers, isomers, stereoisomers thereof.

### Claim 5 (depends on 1)

A compound of claim 1, wherein:
A is phenyl or pyridyl;
B is phenyl or pyridyl;
and pharmaceutically acceptable salts, tautomers, isomers, stereoisomers thereof.

### Claim 6 (depends on 1)

A compound of claim 1, wherein A is phenyl and B is phenyl and pharmaceutically acceptable salts, tautomers, isomers, stereoisomers thereof.

### Claim 7 (depends on 1)

A compound of claim 1, wherein at least one of Ra, Rb, Re and Rd is F and the other(s) is/are hydrogen and pharmaceutically acceptable salts, tautomers, isomers, stereoisomers thereof.

### Claim 8 (depends on 1)

A compound according to claim 1 selected from the group consisting of:
4-amino-3-(N-methylsulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-3-sulfamoyl-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-N-(3,4-difluorophenyl)-3-sulfamoylbenzamide;
4-amino-2-chloro-5-sulfamoyl-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-2-bromo-5-sulfamoyl-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-sulfamoylbenzamide;
4-amino-N-(3-cyano-4-fluorophenyl)-3-sulfamoylbenzamide;
4-amino-N-(3-(difluoromethyl)-4-fluorophenyl)-3-sulfamoylbenzamide;
4-amino-N-(3-chloro-4-fluorophenyl)-3-sulfamoylbenzamide;
4-amino-N-(4-fluoro-3-methylphenyl)-3-sulfamoylbenzamide;
4-amino-2-methyl-5-sulfamoyl-N-(3,4,5-trifluorophenyl)benzamide;
(R)-4-amino-N-(3,4,5-trifluorophenyl)-3-(N-(1,1,1-trifluoropropan-2-yl)sulfamoyl)benzamide;
(S)-4-amino-N-(3,4,5-trifluorophenyl)-3-(N-(1,1,1-trifluoropropan-2-yl)sulfamoyl)benzamide;
4-amino-3-(N-cyclopropylsulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
trans-4-amino-3-(N-(4-hydroxycyclohexyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
cis-4-amino-3-(N-(4-hydroxycyclohexyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
trans-4-amino-5-(N-(4-hydroxycyclohexyl)sulfamoyl)-2-methyl-N-(3,4,5-trifluorophenyl) benzamide;
cis-4-amino-3-(N-3-hydroxycyclobutyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
trans-4-amino-3-(N-3-hydroxycyclobutyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-3-(N-((1R,3R)-3-hydroxycyclopentyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-3-((4-hydroxypiperidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-3-(N-(oxetan-3-yl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
tert-butyl(S)-3-((2-amino-5-((3,4,5-trifluorophenyl)carbamoyl)phenyl)sulfonamido) pyrrolidine-1-carboxylate;
4-amino-3-methyl-5-sulfamoyl-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-3-(N-(3-(hydroxymethyl)oxetan-3-yl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-3-(N-((1-hydroxycyclohexyl)methyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-N-(4-fluoro-3-methylphenyl)-2-methyl-5-sulfamoylbenzamide;
4-amino-5-(N-((1R,4R)-4-hydroxycyclohexyl)sulfamoyl)-2-methyl-N-(3,4,5-trifluorophenyl) benzamide;
trans-4-amino-N-(3-chloro-4-fluorophenyl)-3-(N-(4-hydroxycyclohexyl)sulfamoyl)benzamide;
4-amino-N-(3-(difluoromethyl)-4-fluorophenyl)-3-(N-((1r1R,4r4R)-4-hydroxycyclohexyl) sulfamoyl)benzamide;
trans-4-amino-N-(3-(difluoromethyl)-4-fluorophenyl)-3-(N-(4-hydroxycyclohexyl)sulfamoyl) benzamide;
4-amino-3-(N-((1S,3R)-3-hydroxycyclopentyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-3-(N-((1R,3S)-3-hydroxycyclopentyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-3-((4-hydroxy-4-(hydroxymethyl)piperidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide;
tert-butyl((1R,2S)-2-((2-amino-5-((3,4,5-trifluorophenyl)carbamoyl)phenyl)sulfonamido) cyclopentyl)carbamate;
tert-butyl((1S,2R)-2-((2-amino-5-((3,4,5-trifluorophenyl)carbamoyl)phenyl)sulfonamido) cyclopentyl)carbamate;
4-amino-3-((3-hydroxypyrrolidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide;
4-amino-N-(3-chloro-4-fluorophenyl)-3-((4-hydroxypiperidin-1-yl)sulfonyl)benzamide;
4-amino-N-(3-chloro-4-fluorophenyl)-3-((3-hydroxyazetidin-1-yl)sulfonyl)benzamide;
4-amino-3-(N-(2,3-dihydroxypropyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
trans-4-amino-3-(N-(3-hydroxycyclopentyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
trans-2-amino-5-(N-(4-hydroxycyclohexyl)sulfamoyl)-N-(3,4,5-trifluorophenyl)benzamide;
2-amino-5-((4-hydroxypiperidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide;
(R)-4-amino-2-methyl-N-(3,4,5-trifluorophenyl)-5-(N-(1,1,1-trifluoropropan-2-yl)sulfamoyl) benzamide;
(S)-4-amino-2-methyl-N-(3,4,5-trifluorophenyl)-5-(N-(1,1,1-trifluoropropan-2-yl)sulfamoyl) benzamide;
4-amino-N-(3-chloro-4,5-difluorophenyl)-2-methyl-5-sulfamoylbenzamide;
4-amino-N-(4-fluoro-3-(trifluoromethyl)phenyl)-2-methyl-5-sulfamoylbenzamide;
4-amino-N-(3-(difluoromethyl)-4-fluorophenyl)-2-methyl-5-sulfamoylbenzamide;
4-amino-N-(3-cyano-4-fluorophenyl)-2-methyl-5-sulfamoylbenzamide;
4-amino-N-(3-chloro-4-fluorophenyl)-2-methyl-5-sulfamoylbenzamide;
and pharmaceutically acceptable salts, tautomers, isomers, stereoisomers thereof.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A method for the treatment and/or prevention of an HBV infection and/or a condition related to an HBV infection, comprising administering compound or a pharmaceutically acceptable salt, tautomer, isomer or stereoisomer thereof of claim 1 to a patient in need thereof.

### Claim 11

A method for the treatment and/or prevention of an HBV infection and/or a condition related to an HBV infection, comprising administering a compound of general formula (I):
wherein:
A is a 6-membered aromatic or heteroaromatic ring;
B is a 6-membered aryl optionally containing one or more N atoms;
X is H or NR3R4;
Y is selected from the group consisting of hydrogen, halogen, C1-6alkyl, NH2, NH(C1-6alkyl), N(CH3)2, NHC(O)CH3, OH, saturated or partially unsaturated C3-7cycloalkyl, 5- or 6-membered heteroaryl and CN or is absent;
with the proviso that, when X is H, Y is selected form the group consisting of NH2, NH(C1-6alkyl), N(CH3)2, NHC(O)CH3;
R1 and R2 are each independently selected from H, linear or branched C1-6alkyl, saturated or partially unsaturated
C3-7cycloalkyl, C3-7heterocycloalkyl and heteroaryl, each of said linear or branched C1-6alkyl, saturated or partially unsaturated C3-7cycloalkyl, C3-7heterocycloalkyl or heteroaryl group being optionally substituted with one or more substituents selected from OH, halogen, NH2, NH(C═O)OC1-6alkyl, NH(C1-6alkyl), C1-6alkyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C1-6hydroxyalkyl, 5- or 6-membered heteroaryl, C(═O)C1-6alkyl, C(═O)OC1-6alkyl, OC1-6alkyl, O(CH2)nC3-10cycloalkyl and O(CH2)nC3-10heterocycloalkyl;
or R1 and R2 taken together form with the N atom to which they are attached a saturated or partially unsaturated 3-10 membered heterocyclic ring optionally containing another heteroatom selected from N, O and S, said saturated or partially unsaturated 3-10 membered heterocyclic ring being optionally substituted with one or more substituents selected from OH, halogen, C1-6alkyl, C1-6haloalkyl and (CH2)nR5;
each occurrence of n is independently 0, 1, 2, 3 or 4;
R3 and R4 are each independently H, or linear or branched C1-3alkyl optionally substituted with one or more groups selected from halogen, NH2, NHC1-6alkyl, N(C1-6alkyl)2, NH(C═O)C1-6alkyl, NH(C═O)OC1-6alkyl, OC1-6alkyl, O(CH2)nC3-10cycloalkyl and O(CH2)nC3-10heterocycloalkyl, with the proviso that NR3R4 does not form a saturated, partially saturated or unsaturated heterocyclic ring;
R5 is selected from the group consisting of OH, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, CN, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, heterocyclic ring, aryl and heteroaryl;
Ra is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O) CH3, OH and CN; or is absent;
Rb is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN; or is absent;
Rc is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN; or is absent;
Rd is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN; or is absent;
Re is selected from the group consisting of hydrogen, halogen, C1-3alkyl; or is absent;
Rf is hydrogen, halogen, C1-3alkyl; or is absent;
and pharmaceutically acceptable salts, tautomers, isomers, stereoisomers thereof, to a patient in need thereof.

### Claim 12 (depends on 10)

The method according to claim 10, wherein said condition related to an HBV infection is selected from the group consisting of: chronic hepatitis B, HBV/HDV co-infection, HBV/HCV co-infection, HBV/HIV co-infection, inflammation, necrosis, cirrhosis, hepatocellular carcinoma, hepatic decompensation and hepatic injury from an HBV infection.

### Claim 13 (depends on 10)

The method according to claim 10, wherein said use is in treating, eradicating, reducing, slowing or inhibiting an HBV infection in an individual in need thereof, and/or in reducing the viral load associated with an HBV infection in an individual in need thereof, and/or in reducing reoccurrence of an HBV infection in an individual in need thereof, and/or in inducing remission of hepatic injury from an HBV infection in an individual in need thereof, and/or in prophylactically treating an HBV infection in an individual afflicted with a latent HBV infection.

### Claim 14 (depends on 10)

The method according to claim 10, wherein said treatment is in combination with at least one further therapeutic agent.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the at least one further therapeutic agent is selected from the group consisting of: a therapeutic vaccine; an RNA interference therapeutic/antisense oligonucleotide; an immunomodulator; a STING agonist; a RIG-I modulator; a NKT modulator; an IL agonist; an interleukin or another immune acting protein; a therapeutic and prophylactic vaccine; an immune checkpoint modulator/inhibitor; an HBV entry inhibitor; a cccDNA modulator; an inhibitor of HBV protein espression; an agent targeting HBV RNA; a capsid assembly inhibitor/modulator; a core or X protein targeting agent; a nucleotide analogue; a nucleoside analogue; an interferon or a modified interferon; an HBV antiviral of distinct or unknown mechanism; a cyclophilin inhibitor; a sAg release inhibitor; an HBV polymerase inhibitor; a dinucleotide; a SMAC inhibitor; a HDV targeting agent; a viral maturation inhibitor; a reverse transcriptase inhibitor and an HBV RNA destabilizer or another small-molecule inhibitor of HBV protein expression; or a combination thereof.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said therapeutic vaccine is selected from: HBsAG-HBIG, HB-Vac, ABX203, NASVAC, GS-4774, GX-110 (HB-110E), CVI-HBV-002, RG7944 (INO-1800), TG-1050, FP-02 (Hepsyn-B), AIC649, VGX-6200, KW-2, TomegaVax-HBV, ISA-204, NU-500, INX-102-00557, HBV MVA and PepTcell; wherein said RNA interference therapeutic is selected from: TKM-HBV (ARB-1467), ARB-1740, ARC-520, ARC-521, BB-HB-331, REP-2139, ALN-HBV, ALN-PDL, LUNAR-HBV, GS3228836 and GS3389404; wherein said immunomodulator is a TLR agonist; wherein said RIG-I modulator is SB-9200; wherein said IL agonist or other immune acting protein is INO-9112 or recombinant IL12; wherein said immune checkpoint modulator/inhibitor is BMS-936558 (Opdivo (nivolumab)) or pembrolizumab; wherein said HBV entry inhibitor is Myrcludex B, IVIG-Tonrol or GC-1102; wherein said cccDNA modulator is selected from: a direct cccDNA inhibitor, an inhibitor of cccDNA formation or maintenance, a cccDNA epigenetic modifier and an inhibitor of cccDNA transcription; wherein said capsid assembly inhibitor/modulator, core or X protein targeting agent, direct cccDNA inhibitor, inhibitor of cccDNA formation or maintenance, or cccDNA epigenetic modifier is selected from: BAY 41-4109, NVR 3-778, GLS-4, NZ-4 (W28F), Y101, ARB-423, ARB-199, ARB-596, AB-506, JNJ-56136379, ASMB-101 (AB-V102), ASMB-103, CHR-101, CC-31326, AT-130 and R07049389; wherein said interferon or modified interferon is selected from: interferon alpha (IFN-α), pegylated interferon alpha (PEG-IFN-α), interferon alpha-2a, recombinant interferon alpha-2a, peginterferon alpha-2a (Pegasys), interferon alpha-2b (Intron A), recombinant interferon alpha-2b, interferon alpha-2b XL, peginterferon alpha-2b, glycosylated interferon alpha-2b, interferon alpha-2c, recombinant interferon alpha-2c, interferon beta, interferon beta-1a, peginterferon beta-1a, interferon delta, interferon lambda (IFN-λ), peginterferon lambda-1, interferon omega, interferon tau, interferon gamma (IFN-γ), interferon alfacon-1, interferon alpha-n1, interferon alpha-n3, albinterferon alpha-2b, BLX-883, DA-3021, PI 101 (also known as AOP2014), PEG-infergen, Belerofon, INTEFEN-IFN, albumin/interferon alpha 2a fusion protein, rHSA-IFN alpha 2a, rHSA-IFN alpha 2b, PEG-IFN-SA and interferon alpha biobetter; wherein said HBV antiviral of distinct or unknown mechanism is selected from: AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), AT130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), analogues thereof, REP-9AC (REP-2055), REP-9AC′ (REP-2139), REP-2165 and HBV-0259; wherein said cyclophilin inhibitor is selected from: OCB-030 (NVP-018), SCY-635, SCY-575 and CPI-431-32; wherein said HBV polymerase inhibitor is selected from: entecavir (Baraclude, Entavir), lamivudine (3TC, Zeffix, Heptovir, Epivir, and Epivir-HBV), telbivudine (Tyzeka, Sebivo), clevudine, besifovir, adefovir (hepsera), tenofovir, tenofovir disoproxil fumarate (Viread), tenofovir alafenamide fumarate (TAF), tenofovir disoproxil orotate (DA-2802), tenofovir disopropxil aspartate (CKD-390), AGX-1009, and CMX157; wherein said dinucleotide is SB9200; wherein said SMAC inhibitor is Birinapant; wherein said HDV targeting agent is Lonafamib; wherein said HBV RNA destabilizer or other small-molecule inhibitor of HBV protein expression is RG7834 or AB-452.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt, tautomer, isomer, stereoisomer thereof as defined in claim 1, alone or in combination with at least one further therapeutic agent, and at least one pharmaceutically acceptable excipient.

### Claim 18 (depends on 17)

The pharmaceutical composition according to claim 17, wherein the at least one further therapeutic agent is selected from the group consisting of: a therapeutic vaccine; an RNA interference therapeutic/antisense oligonucleotide; an immunomodulator; a STING agonist; a RIG-I modulator; a NKT modulator; an IL agonist; an interleukin or another immune acting protein; a therapeutic and prophylactic vaccine; an immune checkpoint modulator/inhibitor; an HBV entry inhibitor; a cccDNA modulator; an inhibitor of HBV protein espression; an agent targeting HBV RNA; a capsid assembly inhibitor/modulator; a core or X protein targeting agent; a nucleotide analogue; a nucleoside analogue; an interferon or a modified interferon; an HBV antiviral of distinct or unknown mechanism; a cyclophilin inhibitor; a sAg release inhibitor; an HBV polymerase inhibitor; a dinucleotide; a SMAC inhibitor; a HDV targeting agent; a viral maturation inhibitor; a reverse transcriptase inhibitor and an HBV RNA destabilizer or another small-molecule inhibitor of HBV protein expression; or a combination thereof.

### Claim 19 (depends on 18)

The pharmaceutical composition according to claim 18, wherein said therapeutic vaccine is selected from: HBsAG-HBIG, HB-Vac, ABX203, NASVAC, GS-4774, GX-110 (HB-110E), CVI-HBV-002, RG7944 (INO-1800), TG-1050, FP-02 (Hepsyn-B), AIC649, VGX-6200, KW-2, TomegaVax-HBV, ISA-204, NU-500, INX-102-00557, HBV MVA and PepTcell; wherein said RNA interference therapeutic is selected from: TKM-HBV (ARB-1467), ARB-1740, ARC-520, ARC-521, BB-HB-331, REP-2139, ALN-HBV, ALN-PDL, LUNAR-HBV, GS3228836 and GS3389404; wherein said immunomodulator is a TLR agonist; wherein said RIG-I modulator is SB-9200; wherein said IL agonist or other immune acting protein is INO-9112 or recombinant IL12; wherein said immune checkpoint modulator/inhibitor is BMS-936558 (Opdivo (nivolumab)) or pembrolizumab; wherein said HBV entry inhibitor is Myrcludex B, IVIG-Tonrol or GC-1102; wherein said cccDNA modulator is selected from: a direct cccDNA inhibitor, an inhibitor of cccDNA formation or maintenance, a cccDNA epigenetic modifier and an inhibitor of cccDNA transcription; wherein said capsid assembly inhibitor/modulator, core or X protein targeting agent, direct cccDNA inhibitor, inhibitor of cccDNA formation or maintenance, or cccDNA epigenetic modifier is selected from: BAY 41-4109, NVR 3-778, GLS-4, NZ-4 (W28F), Y101, ARB-423, ARB-199, ARB-596, AB-506, JNJ-56136379, ASMB-101 (AB-V102), ASMB-103, CHR-101, CC-31326, AT-130 and R07049389; wherein said interferon or modified interferon is selected from: interferon alpha (IFN-α), pegylated interferon alpha (PEG-IFN-α), interferon alpha-2a, recombinant interferon alpha-2a, peginterferon alpha-2a (Pegasys), interferon alpha-2b (Intron A), recombinant interferon alpha-2b, interferon alpha-2b XL, peginterferon alpha-2b, glycosylated interferon alpha-2b, interferon alpha-2c, recombinant interferon alpha-2c, interferon beta, interferon beta-1a, peginterferon beta-1a, interferon delta, interferon lambda (IFN-λ), peginterferon lambda-1, interferon omega, interferon tau, interferon gamma (IFN-γ), interferon alfacon-1, interferon alpha-n1, interferon alpha-n3, albinterferon alpha-2b, BLX-883, DA-3021, PI 101 (also known as AOP2014), PEG-infergen, Belerofon, INTEFEN-IFN, albumin/interferon alpha 2a fusion protein, rHSA-IFN alpha 2a, rHSA-IFN alpha 2b, PEG-IFN-SA and interferon alpha biobetter; wherein said HBV antiviral of distinct or unknown mechanism is selected from: AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), AT130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), analogues thereof, REP-9AC (REP-2055), REP-9AC′ (REP-2139), REP-2165 and HBV-0259; wherein said cyclophilin inhibitor is selected from: OCB-030 (NVP-018), SCY-635, SCY-575 and CPI-431-32; wherein said HBV polymerase inhibitor is selected from: entecavir (Baraclude, Entavir), lamivudine (3TC, Zeffix, Heptovir, Epivir, and Epivir-HBV), telbivudine (Tyzeka, Sebivo), clevudine, besifovir, adefovir (hepsera), tenofovir, tenofovir disoproxil fumarate (Viread), tenofovir alafenamide fumarate (TAF), tenofovir disoproxil orotate (DA-2802), tenofovir disopropxil aspartate (CKD-390), AGX-1009, and CMX157; wherein said dinucleotide is SB9200; wherein said SMAC inhibitor is Birinapant; wherein said HDV targeting agent is Lonafamib; wherein said HBV RNA destabilizer or other small-molecule inhibitor of HBV protein expression is RG7834 or AB-452.

### Claim at position 20

20-22. (canceled)

### Claim 23 (depends on 1)

A process for the synthesis of the compound of formula (I) or the pharmaceutically acceptable salt, tautomer, solvate, isomer or stereoisomer thereof as defined in claim 1, said process comprising at least one of the following steps:
reacting a compound of formula (2) with an amine of formula NHR3R4 to obtain a compound of formula (3), wherein A, B, Ra, Rb, Rc, Rd, Re, Rf, Y, R1, R2, R3 and R4 are as defined in claim 1, and Lg is a leaving group such as Cl or F; or
reacting a compound of formula (2) with an ammonium salt such as NH4OH to obtain a compound of formula (4), wherein A, B, Ra, Rb, Rc, Rd, Re, Rf, Y, R1 and R2 are as defined in claim 1, and Lg is a leaving group such as Cl or F; or
reacting a compound of formula (5) with an amine of formula (CH3)2NH or (C1-6)alkylNH2 or with NH4OH to obtain a compound of formula (6) wherein A, B, Ra, Rb, Rc, Rd, Re, Rf, R1 and R2 are as defined in claim 1 and Lg is a leaving group such as Cl or F.
